Deborah Dunsire after three years at Lundbeck: "We're coming up to an inflection point in neuroscience"

Before she took on the role, Deborah Dunsire knew perfectly well that drug development within neurology and psychiatry comes with its own unique challenges compared to cancer, an area in which she has spent the majority of her career. Improvements for brain disorders are on the way, but the road ahead is long, says the CEO at Lundbeck.

Photo: Gregers Tycho/ERH
by ELIZABETH MØNSTED JOHANSEN, translated by Daniel Pedersen

In many ways, it was a journey back in time for Deborah Dunsire when she took the job as CEO at Lundbeck. This is not to say Denmark's life sciences industry is lagging behind the US. Rather, it has something to do specifically with the disease area with which she is now working.

Drug development for central nervous system (CNS) diseases, particularly when it comes to psychiatry, just hasn't been able to match the quantum leaps made the last 20 years within cancer treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today